Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...

The study added to a limited database about the effects of perioperative IO combinations, which have emerged as standard of ...

Source: Getty Images Avelumab plus axitinib was associated with signifi­cantly longer progression-free survival than ...

Top-line, phase 3 results for Bristol-Myers Squibb's humanized monoclonal antibody (mAb) ipilimumab showed a survival benefit in patients with advanced cancer—the first ever phase 3 trial to do so.

An experimental new cancer drug has proven beneficial for a handful of individuals. If all goes to plan, it will be available ...

Previous systemic therapies received, including adjuvant treatment, are listed in the Data Supplement (Table S2). Fig 1. Patient flow. IPI, ipilimumab; NIVO, nivolumab. Median follow-up for OS was ...

Get detailed information on Ipilimumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

The combination produced a response in 45.5% of patients. The combination of sitravatinib, nivolumab, and ipilimumab appears safe and active in patients with advanced clear cell renal cell carcinoma ...

After five years, combination treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) and chemotherapy continues to ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with chemotherapy for the first-line treatment of non-small cell ...